{"ticker": {"uuid": "cc57a295-ae84-4dfd-aac9-a589558e35ee", "symbol": "MANE", "name": "Veradermics, Incorporated", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Veradermics, Incorporated(NYSE:MANE) added to S&P Pharmaceuticals Select Industry Index", "summary": "Veradermics, Incorporated (NYSE: MANE) has been added to the S&P Pharmaceuticals Select Industry Index. This news follows a series of recent announcements, including its addition to the S&P Global BMI Index and several updates on its financial performance and clinical trials. Ver", "url": "https://www.marketscreener.com/news/veradermics-incorporated-nyse-mane-added-to-s-p-pharmaceuticals-select-industry-index-ce7f5cd3d88df623", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:09:16", "published_display": "22 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics, Incorporated(NYSE: MANE) added to S&P Global BMI Index", "summary": "Veradermics, Incorporated (NYSE: MANE) has been added to the S&P Global BMI Index and the S&P Pharmaceuticals Select Industry Index as of June 21, 2026. The company, a late clinical-stage biopharmaceutical firm, is focused on developing therapeutics for aesthetic and dermatologic", "url": "https://www.marketscreener.com/news/veradermics-incorporated-nyse-mane-added-to-s-p-global-bmi-index-ce7f5cd3d881f721", "source_name": "www.marketscreener.com", "published_at": "2026-06-21T23:10:25", "published_display": "21 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Veradermics, Incorporated (MANE) A Good Stock To Buy Now?", "summary": "Veradermics, Incorporated (MANE) is a clinical-stage biopharmaceutical company focused on innovative dermatology therapies. The article highlights a bullish thesis on MANE, citing its pipeline of proprietary topical compounds, ongoing clinical development, and potential for partn", "url": "https://ca.finance.yahoo.com/news/veradermics-incorporated-mane-good-stock-162451041.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-19T09:24:00", "published_display": "19 Jun 2026 09:24", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on NA Companies: Sunbelt Rentals Holdings Inc (SUNB), Veradermics, Incorporated (MANE) and JBS (JBS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxOeHM2Q0k3U0U3aGdGNzYwQ1ZLT04yM05ONFZqUWRFU1VtTnlxXzRGTGNZbVJpVnE5UXNvVjgtTi1lUzhrdUdMQ19NbG9ZSHJtdlR1alB1SjdkeFVZNmhwSVJmMkhEb0hEX3BWS1lDT2JUd1lmSUYwUVk2UnNZM2hXMF9Ja29YZkQ1MExRUEkzMjJqcjVVVWtELXhPZU92RzRWQzYxOVAtQVRteWFTN0dBSWZ1VUFtNHdMUy1EaWpDMUJhNFNjWlQ4b1ZDeEM3WjkwbkMzSXdfOGs1SThYMVUzMG9kQjFRQmpMam1ZeHFBYW05SU9ZWDJZUWF1YXhWM2pPd2MtMGZlaXZqc3VWVWNKajRHb0lLbWZiS21ZT3ladVhXei1LTGxlYg?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-17T13:13:00+00:00", "published_display": "17 Jun 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $138", "summary": "Jefferies has reiterated its Buy rating on Veradermics (MANE.US) and maintained its target price at $138. This indicates the firm's continued positive outlook on the company's stock performance.", "url": "https://www.moomoo.com/news/post/71605997/jefferies-maintains-veradermics-maneus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-06-16T14:39:58", "published_display": "16 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics to Present at Upcoming June Investor Conferences", "summary": "Veradermics, Incorporated announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. CEO Reid Waldman, M.D., and CCO Mark Neuman", "url": "https://www.businesswire.com/news/home/20260528979672/en/Veradermics-to-Present-at-Upcoming-June-Investor-Conferences", "source_name": "Business Wire", "published_at": "2026-05-28T20:10:44", "published_display": "28 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 \u2018302\u2019 Study of VDPHL01 at the 2026 World Congress for Hair Research", "summary": "Veradermics, Incorporated announced that positive topline results from its Phase 2/3 \u2018302\u2019 Study of VDPHL01, an extended-release oral minoxidil formulation for pattern hair loss, will be presented at the 2026 World Congress for Hair Research. The company believes VDPHL01 could be", "url": "https://www.biospace.com/press-releases/veradermics-announces-poster-presentation-on-topline-results-from-phase-2-3-302-study-of-vdphl01-at-the-2026-world-congress-for-hair-research", "source_name": "BioSpace", "published_at": "2026-05-27T14:41:21", "published_display": "27 May 2026 14:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics to present hair loss drug trial data on Friday", "summary": "Veradermics, Incorporated (NYSE:MANE) is set to present positive topline results from its Phase 2/3 Study 302 of VDPHL01, an extended-release oral minoxidil formulation for pattern hair loss, at the 2026 World Congress for Hair Research on Friday, May 30, 2026. The company previo", "url": "https://www.investing.com/news/company-news/veradermics-to-present-hair-loss-drug-trial-data-on-friday-93CH-4711992", "source_name": "Investing.com", "published_at": "2026-05-27T11:41:21", "published_display": "27 May 2026 11:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026", "summary": "Veradermics (NYSE: MANE) is highlighted as one of the best-performing NYSE stocks in 2026, despite reporting a net loss of $27.2 million in Q1 2026 due to increased R&D and G&A expenses for its lead clinical asset. The company achieved a significant milestone with positive Phase ", "url": "https://www.insidermonkey.com/blog/here-is-why-veradermics-mane-is-one-of-the-best-performing-nyse-stocks-so-far-in-2026-1766238/", "source_name": "Insider Monkey", "published_at": "2026-05-20T23:02:00", "published_display": "20 May 2026 23:02", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MANE News | VERADERMICS INC (NYSE:MANE)", "summary": "This article provides recent news updates for VERADERMICS INC (NYSE:MANE). It highlights the company's announcement of two poster presentations at the 2026 Music City SCALE Symposium and its first-quarter 2026 financial results, which also detailed recent corporate and clinical p", "url": "https://www.chartmill.com/stock/quote/MANE/news", "source_name": "ChartMill", "published_at": "2026-05-20T22:14:46", "published_display": "20 May 2026 22:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress", "summary": "Veradermics, Incorporated (NYSE: MANE) announced its first quarter 2026 financial results, highlighting positive topline data from its Phase 2/3 Study \u2018302\u2019 for VDPHL01, an oral treatment for pattern hair loss. The company successfully upsized IPO and follow-on financing generate", "url": "https://www.businesswire.com/news/home/20260512651831/en/Veradermics-Reports-First-Quarter-2026-Financial-Results-and-Highlights-Recent-Corporate-and-Clinical-Progress", "source_name": "Business Wire", "published_at": "2026-05-20T10:09:54", "published_display": "20 May 2026 10:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics (NYSE:MANE) - Earnings & Revenue Performance", "summary": "Veradermics (NYSE:MANE) has reported a significant decline in earnings, with an average annual rate of -154.3%, despite the Pharmaceuticals industry seeing a 9.1% annual growth. The company, however, has recently announced positive Phase 2/3 results for its oral hair-loss candida", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/past", "source_name": "Simply Wall Street", "published_at": "2026-05-16T08:10:54", "published_display": "16 May 2026 08:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MANE Stock Price, Quote & Chart | VERADERMICS INC (NYSE:MANE)", "summary": "This article provides an overview of VERADERMICS INC (NYSE:MANE) stock, including its current price, performance, and key statistics. It also details the company's technical and fundamental analysis ratings from ChartMill, its earnings history, and analyst forecasts. The company ", "url": "https://www.chartmill.com/stock/quote/MANE/profile", "source_name": "ChartMill", "published_at": "2026-05-15T08:40:15", "published_display": "15 May 2026 08:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium", "summary": "Veradermics, Incorporated (NYSE: MANE) announced two E-poster presentations at the 2026 Music City SCALE Symposium on their investigational drug VDPHL01 for pattern hair loss. The presentations will detail comparative analyses of VDPHL01's Phase 2 results against existing minoxid", "url": "https://www.businesswire.com/news/home/20260514238139/en/Veradermics-Announces-Two-Poster-Presentations-on-VDPHL01-at-the-2026-Music-City-SCALE-Symposium", "source_name": "Business Wire", "published_at": "2026-05-14T11:38:50", "published_display": "14 May 2026 11:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Veradermics (NYSE:MANE) - Stock Analysis", "summary": "Veradermics (NYSE:MANE) is a clinical-stage biopharmaceutical company focused on developing therapies for dermatologic and aesthetic conditions, currently specializing in an oral hair loss program. The company's stock is trading significantly below its estimated fair value, with ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics", "source_name": "Simply Wall Street", "published_at": "2026-05-14T07:39:24", "published_display": "14 May 2026 07:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock", "summary": "Veradermics (NYSE:MANE) has reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential new FDA-approved oral treatment. The company also announced recent substantial funding for its programs. The stock has seen sign", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in/amp", "source_name": "Simply Wall Street", "published_at": "2026-05-14T06:38:50", "published_display": "14 May 2026 06:38", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[10-Q] Veradermics, Inc Quarterly Earnings Report", "summary": "Veradermics, Inc. (NYSE: MANE) reported a net loss of $27.2 million for Q1 2026, driven by increased investment in late-stage dermatology programs, with R&D expenses rising to $20.9 million. The company significantly strengthened its balance sheet after a February 2026 IPO, which", "url": "https://www.stocktitan.net/sec-filings/MANE/10-q-veradermics-inc-quarterly-earnings-report-66199bfb45c9.html", "source_name": "Stock Titan", "published_at": "2026-05-12T20:40:51", "published_display": "12 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics (NYSE: MANE) boosts cash with $766.8M raise, advances VDPHL01", "summary": "Veradermics reported a wider net loss of $27.2 million in Q1 2026 due to increased R&D and G&A spending as it accelerates the development of its lead hair-loss drug, VDPHL01. The company successfully raised $766.8 million through an upsized IPO and follow-on offerings, extending ", "url": "https://www.stocktitan.net/sec-filings/MANE/8-k-veradermics-inc-reports-material-event-4cd5154895cf.html", "source_name": "Stock Titan", "published_at": "2026-05-12T12:39:38", "published_display": "12 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Citi Remains Bullish on Veradermics, Incorporated (MANE)", "summary": "Citi has reiterated its \"Buy\" rating and increased its price target on Veradermics, Incorporated (MANE) to $120 following positive Phase 2/3 trial results for its VDPHL01 drug in male pattern hair loss. The company's proprietary extended-release oral minoxidil formulation showed ", "url": "https://www.insidermonkey.com/blog/citi-remains-bullish-on-veradermics-incorporated-mane-1758217/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-05-10T19:12:00", "published_display": "10 May 2026 19:12", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Veradermics (MANE) After A 186% Year To Date Surge?", "summary": "Veradermics (MANE) has seen a significant 186% year-to-date surge, closing at US$107.85. A Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 71.8%, with an estimated intrinsic value of $382.79 per share, despite projecting ongoing free cash flow l", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/is-it-too-late-to-consider-veradermics-mane-after-a-186-year", "source_name": "Simply Wall Street", "published_at": "2026-05-10T05:38:49", "published_display": "10 May 2026 05:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VDPHL01 hair-loss data and $212.9M capital raise for Veradermics (NYSE: MANE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNSVJERktOMEFZQkN5ZUwycWh0blY5X3phZUpLajlEV1A4M1NsM0xCLVhFNExRbENTVS1wdk5xcjRrMEtaT2czN2xLeGVmVmpLVlZEQTU0aVFwMTI3akdLczJXY1ByWmdCaTNOckZwUVg1dTAyd1dMNjg4cjg4ZEx3X3MzWDFEaWNqRE5hR2RTREJBSUoybFVFU2lPU2E2TDBNZGV5SUZ6ekprSnFCaV9SbVI3YS0?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MANE Stock Price and Chart \u2014 NYSE:MANE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE84bGFQX3M5Mmd6UjFDTjRpajhfWHB2SEZkSHUxTV9hSXhOZ3I5d2ZQOWJSNDk1M1lQMm9yc0djQXM3cWlsbmQ0a2xjRWI2dUdJWW00TldjNjZqUQ?oc=5", "source_name": "TradingView", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Veradermics, Incorporated(NYSE:MANE) added to S&P Pharmaceuticals Select Industry Index", "summary": "Veradermics, Incorporated (NYSE: MANE) has been added to the S&P Pharmaceuticals Select Industry Index. This news follows a series of recent announcements, including its addition to the S&P Global BMI Index and several updates on its financial performance and clinical trials. Ver", "url": "https://www.marketscreener.com/news/veradermics-incorporated-nyse-mane-added-to-s-p-pharmaceuticals-select-industry-index-ce7f5cd3d88df623", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:09:16", "published_display": "22 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics, Incorporated(NYSE: MANE) added to S&P Global BMI Index", "summary": "Veradermics, Incorporated (NYSE: MANE) has been added to the S&P Global BMI Index and the S&P Pharmaceuticals Select Industry Index as of June 21, 2026. The company, a late clinical-stage biopharmaceutical firm, is focused on developing therapeutics for aesthetic and dermatologic", "url": "https://www.marketscreener.com/news/veradermics-incorporated-nyse-mane-added-to-s-p-global-bmi-index-ce7f5cd3d881f721", "source_name": "www.marketscreener.com", "published_at": "2026-06-21T23:10:25", "published_display": "21 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Veradermics, Incorporated (MANE) A Good Stock To Buy Now?", "summary": "Veradermics, Incorporated (MANE) is a clinical-stage biopharmaceutical company focused on innovative dermatology therapies. The article highlights a bullish thesis on MANE, citing its pipeline of proprietary topical compounds, ongoing clinical development, and potential for partn", "url": "https://ca.finance.yahoo.com/news/veradermics-incorporated-mane-good-stock-162451041.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-19T09:24:00", "published_display": "19 Jun 2026 09:24", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on NA Companies: Sunbelt Rentals Holdings Inc (SUNB), Veradermics, Incorporated (MANE) and JBS (JBS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxOeHM2Q0k3U0U3aGdGNzYwQ1ZLT04yM05ONFZqUWRFU1VtTnlxXzRGTGNZbVJpVnE5UXNvVjgtTi1lUzhrdUdMQ19NbG9ZSHJtdlR1alB1SjdkeFVZNmhwSVJmMkhEb0hEX3BWS1lDT2JUd1lmSUYwUVk2UnNZM2hXMF9Ja29YZkQ1MExRUEkzMjJqcjVVVWtELXhPZU92RzRWQzYxOVAtQVRteWFTN0dBSWZ1VUFtNHdMUy1EaWpDMUJhNFNjWlQ4b1ZDeEM3WjkwbkMzSXdfOGs1SThYMVUzMG9kQjFRQmpMam1ZeHFBYW05SU9ZWDJZUWF1YXhWM2pPd2MtMGZlaXZqc3VWVWNKajRHb0lLbWZiS21ZT3ladVhXei1LTGxlYg?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-17T13:13:00+00:00", "published_display": "17 Jun 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $138", "summary": "Jefferies has reiterated its Buy rating on Veradermics (MANE.US) and maintained its target price at $138. This indicates the firm's continued positive outlook on the company's stock performance.", "url": "https://www.moomoo.com/news/post/71605997/jefferies-maintains-veradermics-maneus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-06-16T14:39:58", "published_display": "16 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics to Present at Upcoming June Investor Conferences", "summary": "Veradermics, Incorporated announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. CEO Reid Waldman, M.D., and CCO Mark Neuman", "url": "https://www.businesswire.com/news/home/20260528979672/en/Veradermics-to-Present-at-Upcoming-June-Investor-Conferences", "source_name": "Business Wire", "published_at": "2026-05-28T20:10:44", "published_display": "28 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 \u2018302\u2019 Study of VDPHL01 at the 2026 World Congress for Hair Research", "summary": "Veradermics, Incorporated announced that positive topline results from its Phase 2/3 \u2018302\u2019 Study of VDPHL01, an extended-release oral minoxidil formulation for pattern hair loss, will be presented at the 2026 World Congress for Hair Research. The company believes VDPHL01 could be", "url": "https://www.biospace.com/press-releases/veradermics-announces-poster-presentation-on-topline-results-from-phase-2-3-302-study-of-vdphl01-at-the-2026-world-congress-for-hair-research", "source_name": "BioSpace", "published_at": "2026-05-27T14:41:21", "published_display": "27 May 2026 14:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics to present hair loss drug trial data on Friday", "summary": "Veradermics, Incorporated (NYSE:MANE) is set to present positive topline results from its Phase 2/3 Study 302 of VDPHL01, an extended-release oral minoxidil formulation for pattern hair loss, at the 2026 World Congress for Hair Research on Friday, May 30, 2026. The company previo", "url": "https://www.investing.com/news/company-news/veradermics-to-present-hair-loss-drug-trial-data-on-friday-93CH-4711992", "source_name": "Investing.com", "published_at": "2026-05-27T11:41:21", "published_display": "27 May 2026 11:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026", "summary": "Veradermics (NYSE: MANE) is highlighted as one of the best-performing NYSE stocks in 2026, despite reporting a net loss of $27.2 million in Q1 2026 due to increased R&D and G&A expenses for its lead clinical asset. The company achieved a significant milestone with positive Phase ", "url": "https://www.insidermonkey.com/blog/here-is-why-veradermics-mane-is-one-of-the-best-performing-nyse-stocks-so-far-in-2026-1766238/", "source_name": "Insider Monkey", "published_at": "2026-05-20T23:02:00", "published_display": "20 May 2026 23:02", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MANE News | VERADERMICS INC (NYSE:MANE)", "summary": "This article provides recent news updates for VERADERMICS INC (NYSE:MANE). It highlights the company's announcement of two poster presentations at the 2026 Music City SCALE Symposium and its first-quarter 2026 financial results, which also detailed recent corporate and clinical p", "url": "https://www.chartmill.com/stock/quote/MANE/news", "source_name": "ChartMill", "published_at": "2026-05-20T22:14:46", "published_display": "20 May 2026 22:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress", "summary": "Veradermics, Incorporated (NYSE: MANE) announced its first quarter 2026 financial results, highlighting positive topline data from its Phase 2/3 Study \u2018302\u2019 for VDPHL01, an oral treatment for pattern hair loss. The company successfully upsized IPO and follow-on financing generate", "url": "https://www.businesswire.com/news/home/20260512651831/en/Veradermics-Reports-First-Quarter-2026-Financial-Results-and-Highlights-Recent-Corporate-and-Clinical-Progress", "source_name": "Business Wire", "published_at": "2026-05-20T10:09:54", "published_display": "20 May 2026 10:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics (NYSE:MANE) - Earnings & Revenue Performance", "summary": "Veradermics (NYSE:MANE) has reported a significant decline in earnings, with an average annual rate of -154.3%, despite the Pharmaceuticals industry seeing a 9.1% annual growth. The company, however, has recently announced positive Phase 2/3 results for its oral hair-loss candida", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/past", "source_name": "Simply Wall Street", "published_at": "2026-05-16T08:10:54", "published_display": "16 May 2026 08:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MANE Stock Price, Quote & Chart | VERADERMICS INC (NYSE:MANE)", "summary": "This article provides an overview of VERADERMICS INC (NYSE:MANE) stock, including its current price, performance, and key statistics. It also details the company's technical and fundamental analysis ratings from ChartMill, its earnings history, and analyst forecasts. The company ", "url": "https://www.chartmill.com/stock/quote/MANE/profile", "source_name": "ChartMill", "published_at": "2026-05-15T08:40:15", "published_display": "15 May 2026 08:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium", "summary": "Veradermics, Incorporated (NYSE: MANE) announced two E-poster presentations at the 2026 Music City SCALE Symposium on their investigational drug VDPHL01 for pattern hair loss. The presentations will detail comparative analyses of VDPHL01's Phase 2 results against existing minoxid", "url": "https://www.businesswire.com/news/home/20260514238139/en/Veradermics-Announces-Two-Poster-Presentations-on-VDPHL01-at-the-2026-Music-City-SCALE-Symposium", "source_name": "Business Wire", "published_at": "2026-05-14T11:38:50", "published_display": "14 May 2026 11:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics (NYSE:MANE) - Stock Analysis", "summary": "Veradermics (NYSE:MANE) is a clinical-stage biopharmaceutical company focused on developing therapies for dermatologic and aesthetic conditions, currently specializing in an oral hair loss program. The company's stock is trading significantly below its estimated fair value, with ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics", "source_name": "Simply Wall Street", "published_at": "2026-05-14T07:39:24", "published_display": "14 May 2026 07:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics Hair Loss Data And Funding Reignite Interest In MANE Stock", "summary": "Veradermics (NYSE:MANE) has reported positive Phase 2/3 topline results for its oral pattern hair loss candidate VDPHL01, positioning it as a potential new FDA-approved oral treatment. The company also announced recent substantial funding for its programs. The stock has seen sign", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-data-and-funding-reignite-interest-in/amp", "source_name": "Simply Wall Street", "published_at": "2026-05-14T06:38:50", "published_display": "14 May 2026 06:38", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[10-Q] Veradermics, Inc Quarterly Earnings Report", "summary": "Veradermics, Inc. (NYSE: MANE) reported a net loss of $27.2 million for Q1 2026, driven by increased investment in late-stage dermatology programs, with R&D expenses rising to $20.9 million. The company significantly strengthened its balance sheet after a February 2026 IPO, which", "url": "https://www.stocktitan.net/sec-filings/MANE/10-q-veradermics-inc-quarterly-earnings-report-66199bfb45c9.html", "source_name": "Stock Titan", "published_at": "2026-05-12T20:40:51", "published_display": "12 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veradermics (NYSE: MANE) boosts cash with $766.8M raise, advances VDPHL01", "summary": "Veradermics reported a wider net loss of $27.2 million in Q1 2026 due to increased R&D and G&A spending as it accelerates the development of its lead hair-loss drug, VDPHL01. The company successfully raised $766.8 million through an upsized IPO and follow-on offerings, extending ", "url": "https://www.stocktitan.net/sec-filings/MANE/8-k-veradermics-inc-reports-material-event-4cd5154895cf.html", "source_name": "Stock Titan", "published_at": "2026-05-12T12:39:38", "published_display": "12 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Remains Bullish on Veradermics, Incorporated (MANE)", "summary": "Citi has reiterated its \"Buy\" rating and increased its price target on Veradermics, Incorporated (MANE) to $120 following positive Phase 2/3 trial results for its VDPHL01 drug in male pattern hair loss. The company's proprietary extended-release oral minoxidil formulation showed ", "url": "https://www.insidermonkey.com/blog/citi-remains-bullish-on-veradermics-incorporated-mane-1758217/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-05-10T19:12:00", "published_display": "10 May 2026 19:12", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Veradermics (MANE) After A 186% Year To Date Surge?", "summary": "Veradermics (MANE) has seen a significant 186% year-to-date surge, closing at US$107.85. A Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 71.8%, with an estimated intrinsic value of $382.79 per share, despite projecting ongoing free cash flow l", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/is-it-too-late-to-consider-veradermics-mane-after-a-186-year", "source_name": "Simply Wall Street", "published_at": "2026-05-10T05:38:49", "published_display": "10 May 2026 05:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VDPHL01 hair-loss data and $212.9M capital raise for Veradermics (NYSE: MANE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNSVJERktOMEFZQkN5ZUwycWh0blY5X3phZUpLajlEV1A4M1NsM0xCLVhFNExRbENTVS1wdk5xcjRrMEtaT2czN2xLeGVmVmpLVlZEQTU0aVFwMTI3akdLczJXY1ByWmdCaTNOckZwUVg1dTAyd1dMNjg4cjg4ZEx3X3MzWDFEaWNqRE5hR2RTREJBSUoybFVFU2lPU2E2TDBNZGV5SUZ6ekprSnFCaV9SbVI3YS0?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MANE Stock Price and Chart \u2014 NYSE:MANE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE84bGFQX3M5Mmd6UjFDTjRpajhfWHB2SEZkSHUxTV9hSXhOZ3I5d2ZQOWJSNDk1M1lQMm9yc0djQXM3cWlsbmQ0a2xjRWI2dUdJWW00TldjNjZqUQ?oc=5", "source_name": "TradingView", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 29, "sentiment_summary": {"positive": 20, "negative": 1, "neutral": 8, "score": 67, "total": 29, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 77, "events": [{"event": "earnings", "label": "Earnings", "weight": 7.29, "count": 15}, {"event": "general", "label": "Market update", "weight": 4.95, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 93.87, "latest_week": "2026-06-19", "one_week_move": -2.3, "four_week_move": -7.6, "twelve_week_move": 43.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 28.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 72.3926, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.3% over one week, -7.6% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 77, "badges": ["Sentiment-trend disagreement", "Positive but stretched"], "opportunities": [], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive.", "Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Market source", "count": 5}, {"label": "Simply Wall Street", "count": 4}, {"label": "Business Wire", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "www.marketscreener.com", "count": 2}, {"label": "Insider Monkey", "count": 2}, {"label": "ChartMill", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 22}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 15}, {"label": "Market update", "count": 9}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "67/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "22", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.3% over one week, -7.6% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Veradermics, Incorporated(NYSE:MANE) added to S&P Pharmaceuticals Select Industry Index"}], "updated_at": "2026-06-23T00:01:45.396113+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}